Novo Nordisk A/S

Tweet this page
Registration as it was on 16 Mar 2023
How to read and use this data card.
Download this datacard


Lobbying Costs

600,000€ - 699,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

1.45 Fte (8)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    Novo Nordisk A/S

    EU Transparency Register

    29570313329-11 First registered on 13 Mar 2010

    Goals / Remit

    Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.

    Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases.

    We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

    We employ more than 50,000 people in 80 offices around the world, and market our products in 170 countries.

    Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line). This commitment is demonstrated through its values and its environmental and social responsibility policies.

    The Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its companies’ operations and to make contributions to scientific, humanitarian and social progress.

    Main EU files targeted

    EU pharmaceutical-related legislation (in the fields of health, research and technology, IHI, environment, enterprise and trade).


    Head Office
    Novo Nordisk A/S Novo Allé, 1
    Bagsværd 2880
    EU Office
    Square de Meeûs 37
    Brussels null - 1000


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    3 accreditations were / are live (in bold) for the selected state of 01 Apr 2023

    Name Start date End Date
    Mr Christian JUUL NYHUS 16 Feb 2023 15 Feb 2024
    Mr Alexander VON WILDENRATH LØVGREEN 16 Feb 2023 15 Feb 2024
    Mr Matthew CLAY 07 Jun 2022 06 Jun 2023
    Mr Vincent CLAY 07 Jun 2022 27 Jun 2022
    Jeppe Torp VESTENTOFT 03 Dec 2019 01 Aug 2020
    Ms Victoria Breck 30 Nov 2019 28 Nov 2020
    Ms Ane Sofie Böhm Nielsen 23 Sep 2014 19 Sep 2015
    Mr Troels Anders RYE-ANDERSEN 08 Aug 2014 06 Aug 2015
    Mr Morten Frank Pedersen 19 Sep 2013 18 Sep 2014
    Ms Engelbertha Maria Rouweler 17 Sep 2013 14 Mar 2014
    Mr Neil David Causey 17 Sep 2013 14 Sep 2014
    Mr Troels Anders RYE-ANDERSEN 07 Jun 2013 06 Jun 2014
    Mr Troels Anders RYE-ANDERSEN 16 Jan 2012 08 Feb 2013

    Complementary Information

    A range of Novo Nordisk colleagues contribute their expertise to activities covered by the Register, directly or through trade associations. We have used 10% relevant working time as the threshold for including colleagues in our FTE calculations.

    We have updated our annual declaration for 2022 using EFPIA membership costs from 2021. EFPIA are preparing their Transparency Register-related costs ahead of their annual declaration, which is due later this year. We will update our declaration for 2022 when we have these revised costs. Novo Nordisk’s overall contribution to EFPIA is similar in 2022 to 2021 so we consider this an appropriate approach.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Companies & groups

  • Networking


    Novo Nordisk is member of:

    - EFPIA - European Federation of Pharmaceutical Industries and Associations

    - Danish Chamber of Commerce

    - MedTech Europe (ceased at end 2022)

    - Science|Business

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    600,000€ - 699,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    rud pedersen 10,000€ - 24,999€
    copenhagen economics 10,000€ - 24,999€
    the trade council, ministry of foreign affairs (denmark) 0€ - 10,000€

    Intermediaries for current year

    copenhagen economics
    rud pedersen

    Closed year Costs

    600,000€ - 699,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)


    Other activities

    Novo Nordisk's goals with its involvement with EU institutions are:

    - to improve conditions for prevention, treatment and care in Europe to address unmet needs

    - to support the voice of people living with or at risk of developing serious chronic diseases

    - to increase Europe´s competitiveness as a location for Research and Development

  • Meetings


    5 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

Download this datacard